Skip to main content

Company That just Released World’s First Saliva Test for Autism Opens Up Investment Opportunity to the Public

Quadrant Biosciences Inc, a leading developer of epigenetic diagnostic solutions, including the world’s first saliva test for autism, announced that it is now offering common shares of the company (at a price of $3/share, with a minimum investment of $300) through equity crowdfunding platform Wefunder.